Otonomy Inc (OTIC):企業の財務・戦略的SWOT分析

◆英語タイトル:Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH139129FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥48,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Otonomy Inc (OTIC) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients and otitis externa. Its pipeline portfolio encompasses Otividex for the treatment of meniere’s disease; OTO-313 for the treatment of tinnitus; OTO-510 for the treatment of cisplatin-induced hearing loss; OTO-413 for the treatment of synaptopathy hearing loss; and OTO-6XX for the treatment of severe hearing loss. The company is also investigating a preclinical program on GJB2 gener therapy in collaboration with AGTC for treatment of congenital hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.

Otonomy Inc Key Recent Developments

Nov 04,2020: Otonomy reports third quarter 2020 financial results and provides corporate update
Aug 04,2020: Otonomy reports second quarter 2020 financial results and provides corporate update
Jun 15,2020: Otonomy provides update on clinical trials and development programs
May 07,2020: Otonomy reports first quarter 2020 financial results and provides corporate update
Apr 09,2020: Otonomy provides business update related to covid-19 pandemic

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Otonomy Inc – Key Facts
Otonomy Inc – Key Employees
Otonomy Inc – Key Employee Biographies
Otonomy Inc – Major Products and Services
Otonomy Inc – History
Otonomy Inc – Company Statement
Otonomy Inc – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
Otonomy Inc – Business Description
R&D Overview
Otonomy Inc – Corporate Strategy
Otonomy Inc – SWOT Analysis
SWOT Analysis – Overview
Otonomy Inc – Strengths
Otonomy Inc – Weaknesses
Otonomy Inc – Opportunities
Otonomy Inc – Threats
Otonomy Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Otonomy Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 04, 2020: Otonomy reports third quarter 2020 financial results and provides corporate update
Aug 04, 2020: Otonomy reports second quarter 2020 financial results and provides corporate update
Jun 15, 2020: Otonomy provides update on clinical trials and development programs
May 07, 2020: Otonomy reports first quarter 2020 financial results and provides corporate update
Apr 09, 2020: Otonomy provides business update related to covid-19 pandemic
Feb 27, 2020: Otonomy reports fourth quarter and full year 2019 financial results and provides corporate update
Jan 09, 2020: Otonomy provides corporate and product pipeline update and financial guidance
Nov 05, 2019: Otonomy reports third quarter 2019 financial results and provides corporate update
Aug 01, 2019: Otonomy reports second quarter 2019 financial results and provides corporate update
May 06, 2019: Otonomy reports first quarter 2019 financial results and provides corporate update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Otonomy Inc, Key Facts
Otonomy Inc, Key Employees
Otonomy Inc, Key Employee Biographies
Otonomy Inc, Major Products and Services
Otonomy Inc, History
Otonomy Inc, Key Competitors
Otonomy Inc, Ratios based on current share price
Otonomy Inc, Annual Ratios
Otonomy Inc, Annual Ratios (Cont...1)
Otonomy Inc, Interim Ratios
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Otonomy Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Otonomy Inc (OTIC):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UTC Engenharia SA:企業の戦略的SWOT分析
    UTC Engenharia SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Serco Group plc:企業の戦略・SWOT・財務情報
    Serco Group plc - Strategy, SWOT and Corporate Finance Report Summary Serco Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sothema (SOT):企業の財務・戦略的SWOT分析
    Sothema (SOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Fate Therapeutics Inc (FATE):企業の財務・戦略的SWOT分析
    Fate Therapeutics Inc (FATE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329):企業の財務・戦略的SWOT分析
    Summary Tianjin Zhongxin Pharmaceutical Group Corp Ltd (TZPG) carries out the manufacturing of traditional Chinese medicine, western medicine and health products. The company offers Chinese patent medicines, Chinese medicinal materials, chemical medicines, dietary supplements, pharmaceutical raw mat …
  • MAN Energy Solutions SE:企業の戦略的SWOT分析
    MAN Energy Solutions SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Komatsu Ltd.:企業の戦略・SWOT・財務情報
    Komatsu Ltd. - Strategy, SWOT and Corporate Finance Report Summary Komatsu Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Asos Plc:企業の戦略・SWOT・財務分析
    Asos Plc - Strategy, SWOT and Corporate Finance Report Summary Asos Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Tieto Corp (TIETO):企業の財務・戦略的SWOT分析
    Tieto Corp (TIETO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • hVIVO Plc (HVO):企業の財務・戦略的SWOT分析
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • CollPlant Ltd (CLGN):医療機器:M&Aディール及び事業提携情報
    Summary CollPlant Holdings Ltd (CollPlant) is a regenerative medicine company that carries out development and commercialization of tissue repair products. The company offers orthobiologics, wound care, and pipeline products. Its orthobiologics products include VergenixSTR and VergenixBVF. CollPlant …
  • AmeriGas Partners LP (APU):企業の財務・戦略的SWOT分析
    Summary AmeriGas Partners LP (AmeriGas) is an oil and gas company that distributes propane liquid. The company supply propane for residential and business applications. AmeriGas propane is used in residential applications such as propane home heating, propane water heating, and propane for drying cl …
  • ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析
    Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide …
  • Mondi Plc (MNDI):企業の戦略的SWOT分析
    Mondi Plc (MNDI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • ERG Power Generation SpA:企業の戦略的SWOT分析
    ERG Power Generation SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Taurus International MFG, Inc.:企業の戦略・SWOT・財務情報
    Taurus International MFG, Inc. - Strategy, SWOT and Corporate Finance Report Summary Taurus International MFG, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Praxair, Inc.:企業のM&A・事業提携・投資動向
    Praxair, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Praxair, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Kosmos Energy Ltd (KOS):石油・ガス:M&Aディール及び事業提携情報
    Summary Kosmos Energy Ltd. (Kosmos) is an independent oil and gas exploration and production company. Its primary areas of operation are frontier and emerging areas along the Atlantic Margin. The company’s asset portfolio includes existing production and development projects offshore Ghana, discover …
  • Cardiva Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cardiva Medical Inc (Cardiva) designs, develops and commercializes of vascular access management products. The major products of the company include VASCADE vascular closure system (VCS) for femoral arterial access site closure post-diagnostic and interventional endovascular procedures; and …
  • Pepticom Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pepticom Ltd (Pepticom) is a drug discovery and development company focused on novel peptide drug candidates. The company's artificial intelligence platform for peptide design models based on the target's solved crystal structure of the target protein. Its products includes copaxone, used fo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆